Dr Todd N Smith, DPM | |
Pine Ridge Ihs Hospital, Pine Ridge, SD 57770-1201 | |
(605) 867-3358 | |
(605) 867-3271 |
Full Name | Dr Todd N Smith |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | Pine Ridge Ihs Hospital, Pine Ridge, South Dakota |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1912973603 | NPI | - | NPPES |
000K3526 | Medicaid | NM | |
HSZ196 | Other | NM | MEDICARE PART B |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
213ES0103X | Podiatrist - Foot & Ankle Surgery | 210 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Todd N Smith, DPM Po Box 1222, Pine Ridge, SD 57770-1222 Ph: (605) 867-3043 | Dr Todd N Smith, DPM Pine Ridge Ihs Hospital, Pine Ridge, SD 57770-1201 Ph: (605) 867-3358 |
News Archive
CVS Caremark announced today that the Pharmacy Benefit Management Institute (PBMI) awarded the company and its PBM client ArcelorMittal, the world's largest steel company, the 2011 Rx Benefit Innovation Award. The award recognizes the Pharmacy Advisor program, which was developed by CVS Caremark to manage costs, improve medication adherence and close gaps in care for members with diabetes.
The prevalence of type 2 diabetes among 25,000 patients with familial hypercholesterolemia (a genetic disorder characterized by high low-density lipoprotein [LDL] cholesterol levels) was significantly lower than among unaffected relatives, with the prevalence varying by the type of gene mutation, according to a study in the March 10 issue of JAMA.
Geron Corporation today announced that the U.S. Patent and Trademark Office, Board of Patent Appeals and Interferences, has granted Geron's request to declare an interference between a patent application owned by Geron and U.S. Patent No. 7,510,876 (the ‘876 patent) owned by Novocell, Inc.
Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, up to $25.0 million of shares of its Series 8 Non-Convertible Preferred Stock, warrants to purchase up to 22,563,177 shares of common stock and an additional investment right to purchase up to $25.0 million of shares of its Series 9 Convertible Preferred Stock, in a registered offering to a single life sciences institutional investor.
› Verified 6 days ago